Ozempic and Cancer Risk — What We Know

Ozempic and Cancer Risk — Reading Between the Headlines

28 min · 7 de abr de 2026
Portada del episodio Ozempic and Cancer Risk — Reading Between the Headlines

Descripción

Ben Synth explores the conflicting evidence on GLP-1 drugs and cancer risk, analyzing why a French study showed increased thyroid cancer risk while a 2.5-million-patient international study found none. He examines detection bias, study design, and emerging protective effects against other cancers. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Ozempic and Cancer Risk — What We Know!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

4 episodios

episode Ozempic and Cancer Risk — Uncover what the science really says with Dr. Ben Synth artwork

Ozempic and Cancer Risk — Uncover what the science really says with Dr. Ben Synth

Join Dr. Ben Synth as he cuts through the noise surrounding Ozempic and cancer risk, revealing why the truth is far more fascinating than fear-mongering headlines. From thyroid cancer warnings to research suggesting these drugs might actually prevent cancer, you'll learn to navigate contradictory medical evidence with clarity. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202638 s
episode Ozempic and Cancer Risk — What We Know - The Plot Twist artwork

Ozempic and Cancer Risk — What We Know - The Plot Twist

Host Ben Synth explores how GLP-1 drugs like Ozempic, which carry thyroid cancer warnings from rodent studies, are showing unexpected cancer-protective effects in humans. New research reveals colon cancer patients on these medications have half the mortality rate, while studies show reduced risk across twelve obesity-related cancers—challenging assumptions about these widely-prescribed medications. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202626 min
episode Ozempic and Cancer Risk — What We Know - The Black Box That Started It All artwork

Ozempic and Cancer Risk — What We Know - The Black Box That Started It All

AI host Ben Synth explores the FDA's thyroid cancer warning on GLP-1 drugs like Ozempic, revealing it stems from rodent studies, not human data. Ben examines massive multinational studies showing no substantial cancer risk increase, discusses detection bias explaining apparent associations, and highlights emerging research suggesting these medications may actually protect against certain cancers. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7 de abr de 202623 min